REPLIGEN CORP Other Current Assets
REPLIGEN CORP (RGEN) had Other Current Assets of $21.57 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:OtherAssetsCurrent · last filed 2026-02-26
- 2025-12-31: Other Assets, Current $21.57M.
- 2024-12-31: Other Assets, Current $12.13M.
- 2023-12-31: Other Assets, Current $13.32M.
- 2022-12-31: Other Assets, Current $10.27M.
| Period end | Other Assets, Current | Other Assets, Current as first filed |
|---|---|---|
| 2025-12-31 | $21.57M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $12.13M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $13.32M 10-K · filed 2025-03-14 | |
| 2022-12-31 | $10.27M 10-K/A · filed 2024-11-18 | |
| 2021-12-31 | $8.41M 10-K · filed 2023-02-22 | |
| 2020-12-31 | $9.49M 10-K · filed 2022-02-17 | |
| 2019-12-31 | $1.46M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $697.00K 10-K · filed 2020-02-26 | |
| 2017-12-31 | $218.00K 10-K · filed 2019-03-01 | |
| 2016-12-31 | $71.00K 10-K · filed 2018-02-22 | $42.00K 10-K · filed 2017-02-23 |
| 2015-12-31 | $22.00K 10-K · filed 2017-02-23 | |
| 2014-12-31 | $23.00K 10-K · filed 2016-02-25 | $27.77K 10-K · filed 2015-03-17 |
| 2013-12-31 | $33.35K 10-K · filed 2015-03-17 | |
| 2012-12-31 | $36.73K 10-K · filed 2014-03-14 | |
| 2011-12-31 | $82.30K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |